Q2 2026 Ginkgo Bioworks Holdings Inc Earnings Call Transcript
Key Points
- Ginkgo Bioworks Holdings Inc (DNA) has been selected to build autonomous labs for MIT, Caltech, Maryland, and Northwestern, expanding its presence in the academic research sector.
- The company's autonomous lab, Nebula, has been expanded to 105 RACs and is running 24/7, demonstrating significant operational scale and capability.
- Ginkgo Bioworks Holdings Inc (DNA) launched a new ADME service that is priced at $199 per panel, significantly undercutting Western ($2,000-$5,000) and Chinese ($1,000-$2,500) CRO competitors.
- The company reaffirmed its full-year 2026 cash burn guidance of $125 million to $150 million, reflecting improved cost efficiency and a strong cash position of $302 million.
- Ginkgo Bioworks Holdings Inc (DNA) is capitalizing on a growing US policy push for autonomous labs, as highlighted by a new OSTP report and NSF's $400 million program for cloud laboratories.
- Ginkgo Bioworks Holdings Inc (DNA) reported a 48% year-over-year decline in Q2 2026 revenue, down to $20 million from $38 million.
- Adjusted EBITDA loss widened to negative $36 million in Q2 2026, compared to a negative $25 million loss in the same period last year.
- The company's cash burn increased to $45 million in Q2 2026, up from $38 million in Q2 2025, despite a slight decrease for the first half of the year.
- Ginkgo Bioworks Holdings Inc (DNA) is carrying $14 million in excess lab space costs, which are not related to driving revenue and could be mitigated through subleasing.
- The company is not providing revenue guidance and does not break out revenue for its autonomous lab segment, creating uncertainty about the financial impact of its new strategic initiatives.
I'm Daniel Marshall, Senior Manager of Communications and ownership. I'm joined by Jason Kelly, our Co-Founder and CEO; and Steve Cohen, our CFO. Thanks, as always, for joining us. We're looking forward to updating you on our progress.
As a reminder, during the presentation today, we will be making forward-looking statements, which involve risks and uncertainties. Please refer to our filings with the SEC to learn more about these risks and uncertainties, including our most recent 10-K.
Today, in addition to updating you on the quarter results, we're going to make the argument that autonomous labs are an imperative for American Science. We're also going to provide insight into how we are going to scale the capabilities of Nebula, our autonomous lab in Boston, and share an update on how we are getting autonomous labs like enhance the next generation of scientists. As usual, we'll end with the Q&A session, and I'll take questions from analysts, investors, and the public can submit those
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
